44 results on '"Labrijn, Aran F."'
Search Results
2. Impact of structural modifications of IgG antibodies on effector functions
3. The Influence of Human IgG Subclass and Allotype on Complement Activation
4. Bispecific antibodies: a mechanistic review of the pipeline
5. Fig S3 from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
6. Supplementary Figure Legends from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
7. Data from CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
8. Hitting Ebola, to the power of two
9. Broadly Cross-Reactive HIV-1-Neutralizing Human Monoclonal Fab Selected for Binding to gp120-CD4-CCR5 Complexes
10. Mutation of the TGN1412 anti‐CD28 Monoclonal Antibody Lower Hinge Confers Specific FcγRIIb Binding and Retention of Super‐Agonist Activity
11. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
12. Efficient generation of stable bispecific lgG1 by controlled Fab-arm exchange
13. When binding is enough: nonactivating antibody formats
14. Opening the door to innovation
15. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
16. Production of stable bispecific IgG1 by controlled Fab-arm exchange: Scalability from bench to large-scale manufacturing by application of standard approaches
17. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation
18. Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG
19. Fab-arm exchange: Whatʼs in a name?
20. FcγR Binding and ADCC Activity of Human IgG Allotypes
21. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
22. CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
23. Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange
24. Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies
25. Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange
26. Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models
27. Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys
28. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope
29. Impact of IgG oligomerization state on the potency of complement-dependent cytotoxicity
30. Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen
31. Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange.
32. Controlled Fab-arm exchange for the generation of stable bispecific IgG1
33. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
34. Fab-arm exchange
35. Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3–CH3 Interaction Strength
36. Quantitative Analysis of the Interaction Strength and Dynamics of Human IgG4 Half Molecules by Native Mass Spectrometry
37. Reply to Fab-arm exchange
38. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
39. Improved Breadth and Potency of an HIV-1-Neutralizing Human Single-chain Antibody by Random Mutagenesis and Sequential Antigen Panning
40. Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1
41. A Novel Human Antibody against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12
42. Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library
43. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41
44. <atl>Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.